AU2014204043A1 - Characterizing a glatiramer acetate related drug product - Google Patents

Characterizing a glatiramer acetate related drug product Download PDF

Info

Publication number
AU2014204043A1
AU2014204043A1 AU2014204043A AU2014204043A AU2014204043A1 AU 2014204043 A1 AU2014204043 A1 AU 2014204043A1 AU 2014204043 A AU2014204043 A AU 2014204043A AU 2014204043 A AU2014204043 A AU 2014204043A AU 2014204043 A1 AU2014204043 A1 AU 2014204043A1
Authority
AU
Australia
Prior art keywords
cells
expression
level
glatiramer acetate
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2014204043A
Other languages
English (en)
Inventor
Maksym ARTOMOV
Shlomo BAKSHI
Kevin Daniel FOWLER
Jason Michael Funt
Rivka SCHWARTZ
Fadi George TOWFIC
Benjamin James ZESKIND
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teva Pharmaceutical Industries Ltd
Original Assignee
Teva Pharmaceutical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51061235&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2014204043(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teva Pharmaceutical Industries Ltd filed Critical Teva Pharmaceutical Industries Ltd
Publication of AU2014204043A1 publication Critical patent/AU2014204043A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2014204043A 2013-01-04 2014-01-02 Characterizing a glatiramer acetate related drug product Abandoned AU2014204043A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361749228P 2013-01-04 2013-01-04
US61/749,228 2013-01-04
US201361819481P 2013-05-03 2013-05-03
US61/819,481 2013-05-03
PCT/US2014/010103 WO2014107533A2 (en) 2013-01-04 2014-01-02 Characterizing a glatiramer acetate related drug product

Publications (1)

Publication Number Publication Date
AU2014204043A1 true AU2014204043A1 (en) 2015-08-13

Family

ID=51061235

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2014204043A Abandoned AU2014204043A1 (en) 2013-01-04 2014-01-02 Characterizing a glatiramer acetate related drug product

Country Status (17)

Country Link
US (1) US20140193827A1 (enExample)
EP (1) EP2941274A4 (enExample)
JP (1) JP2016504039A (enExample)
KR (1) KR20150111945A (enExample)
CN (1) CN105228651A (enExample)
AU (1) AU2014204043A1 (enExample)
BR (1) BR112015016169A2 (enExample)
CA (1) CA2896957A1 (enExample)
CL (1) CL2015001915A1 (enExample)
EA (1) EA201591251A1 (enExample)
HK (1) HK1216299A1 (enExample)
IL (2) IL239692A0 (enExample)
MX (1) MX2015008754A (enExample)
PE (1) PE20151980A1 (enExample)
SG (1) SG11201505210RA (enExample)
WO (1) WO2014107533A2 (enExample)
ZA (1) ZA201505367B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ598661A (en) 2009-08-20 2013-02-22 Yeda Res & Dev Low frequency glatiramer acetate therapy
USRE49251E1 (en) 2010-01-04 2022-10-18 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
CA2814500A1 (en) 2010-10-11 2012-04-19 Teva Pharmaceutical Industries Ltd Cytokine biomarkers as predictive biomarkers of clinical response for glatiramer acetate
HK1200274A1 (en) 2011-10-10 2015-08-07 Teva Pharmaceutical Industries Ltd. Single nucleotide polymorphisms useful to predict clinical response for glatiramer acetate
HK1213830A1 (zh) 2012-10-10 2016-07-15 Teva Pharmaceutical Industries Ltd. 用於预测醋酸格拉替雷临床反应的生物标志物
CN105377308B (zh) 2013-03-14 2019-07-26 迈兰公司 醋酸格拉替雷响应生物标志物mRNA效力测定
UY35790A (es) 2013-10-21 2015-05-29 Teva Pharma Marcadores genéticos que predicen la respuesta al acetato de glatiramer
US9995734B2 (en) 2013-10-24 2018-06-12 Mylan Inc. Human T cell line assay for evaluating the immunologic identity of glatiramer acetate preparations
US9155775B1 (en) 2015-01-28 2015-10-13 Teva Pharmaceutical Industries, Ltd. Process for manufacturing glatiramer acetate product
JP2018506275A (ja) 2015-01-28 2018-03-08 ジェネンテック， インコーポレイテッド 多発性硬化症の遺伝子発現マーカー及び治療
WO2017087866A1 (en) 2015-11-20 2017-05-26 Grand Valley State University Nato3 mutant polypeptides and uses thereof
US12097292B2 (en) 2016-08-28 2024-09-24 Mapi Pharma Ltd. Process for preparing microparticles containing glatiramer acetate
CN109982712A (zh) 2016-08-31 2019-07-05 Mapi医药公司 包含醋酸格拉替雷的储库系统
JP7276664B2 (ja) * 2016-11-11 2023-05-18 ロングエバーオン インコーポレイテッド 細胞性及び体液性免疫を達成するためのヒト間葉系幹細胞を使用する方法
CN110382052A (zh) 2017-03-26 2019-10-25 Mapi医药公司 用于治疗进展型形式的多发性硬化症的格拉替雷储库系统
CN115044684A (zh) * 2022-06-22 2022-09-13 四川大学华西医院 lcn2基因作为生物标记物在检测Stat5基因是否缺失中的用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7429374B2 (en) * 2001-12-04 2008-09-30 Teva Pharmaceutical Industries, Ltd. Process for the measurement of the potency of glatiramer acetate
WO2004028339A2 (en) * 2002-09-27 2004-04-08 Brigham And Women's Hospital, Inc. Treatment of patients with multiple sclerosis based on gene expression changes in central nervous system tissues
JP2009509142A (ja) * 2005-09-19 2009-03-05 エーザイ・アール・アンド・ディー・マネジメント株式会社 調節性Ｔ細胞機能をモジュレート（ｍｏｄｕｌａｔｅ）し得るＧＰＲ８３アゴニストおよびＧＰＲ８３アンタゴニストを同定するための方法
US8753833B2 (en) * 2007-06-21 2014-06-17 Momenta Pharmaceuticals, Inc. Copolymer assay
EP2365825A1 (en) * 2008-11-18 2011-09-21 Crossbeta Biosciences B.V. Cross-beta structures as carriers in vaccines
NZ598661A (en) * 2009-08-20 2013-02-22 Yeda Res & Dev Low frequency glatiramer acetate therapy

Also Published As

Publication number Publication date
CL2015001915A1 (es) 2016-11-11
BR112015016169A2 (pt) 2017-07-11
EA201591251A1 (ru) 2016-05-31
KR20150111945A (ko) 2015-10-06
IL252547A0 (en) 2017-07-31
IL239692A0 (en) 2015-08-31
SG11201505210RA (en) 2015-07-30
EP2941274A4 (en) 2016-11-16
PE20151980A1 (es) 2016-01-15
ZA201505367B (en) 2016-11-30
MX2015008754A (es) 2016-04-11
WO2014107533A2 (en) 2014-07-10
EP2941274A2 (en) 2015-11-11
CN105228651A (zh) 2016-01-06
US20140193827A1 (en) 2014-07-10
HK1216299A1 (zh) 2016-11-04
WO2014107533A3 (en) 2015-01-29
CA2896957A1 (en) 2014-07-10
JP2016504039A (ja) 2016-02-12

Similar Documents

Publication Publication Date Title
AU2014204043A1 (en) Characterizing a glatiramer acetate related drug product
US11806555B2 (en) Methods for treating hair loss disorders
US10870885B2 (en) Dendritic cell response gene expression, compositions of matters and methods of use thereof
Cirillo et al. Severe combined immunodeficiency—an update
US20240043934A1 (en) Pancreatic ductal adenocarcinoma signatures and uses thereof
GB2627085A (en) Methods and systems for analysing nucleic acid molecules
AU2014284124A1 (en) Biomarker identification
AU2012336120A1 (en) Method of predicting breast cancer prognosis
US20250019770A1 (en) Circulating tumor dna fraction and uses thereof
US20230132281A1 (en) Rna sequencing to diagnose sepsis
US20250201339A1 (en) Use of combined cd274 copy number changes and tmb to predict response to immunotherapies
JP2026505163A (ja) Ｅ３リガーゼファミリーの機能及び相互作用
US20220154282A1 (en) Detection means, compositions and methods for modulating synovial sarcoma cells
Bhardwaj et al. Identification of hub genes in placental dysfunction and recurrent pregnancy loss through transcriptome data mining: a meta-analysis
Kawahara et al. Defining contributions of paternally methylated imprinted genes at the Igf2-H19 and Dlk1-Gtl2 domains to mouse placentation by transcriptomic analysis
CA3116005A1 (en) Use of mucosal transcriptomes for assessing severity of ulcerative colitis and responsiveness to treatment
Ren et al. Distinct molecular processes in placentae involved in two major subtypes of preeclampsia
Alyafie Application of Genomics for the Precision Diagnosis of Inborn Errors of Immunity
Lopes et al. Long non-coding RNA HCP5 is a key regulator of cDC2s function: implications for Sjögren’s Syndrome
EP4580752A1 (en) Treatments for prurigo nodularis
Ögmundsdóttir et al. Familial predisposition to monoclonal gammopathies: deviations in B-cell biology

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period